CVMASEHealthcare·Biotechnology#445 in industry

CEL-SCI Corporation

-49.8% · 90d

$3.27

+0.07 (+2.03%)

News

No News Yet

Press releases and SEC filings for CVM will appear here as they are published.

Check back later for updates

Key Data

Market Cap$27.6M

Open$3.21

Prev Close$3.20

Day Range$3.19 – $3.27

52W Range$1.98 – $13.48

Volume51,874

P/E (TTM)—

EPS$-3.70

Dividend Yield—

Beta1.00

Price Target$25.00(+665.7%)

Next Earnings2026-02-12

Analyst Ratings

Strong Buy1 analysts

Buy 1Hold 0Sell 0

About

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Healthcare · Biotechnology

cel-sci.com